Aug, 2018

First report of dolutegravir unbond plasma concentrations during pregnancy in HIV-positive women


Authors: Bollen P, Colbers A, Schalkwijk S, Velthoven-Graafland K, Konopnicki D, Weizsacker K, Hidalgo Tenorio C, van Crevel R, Burger D, on behalf of the PANNA network

Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore




Aug, 2018

Elvitegravir pharmacokinetics during pregnancy and postpartum


Authors: Colbers A, Schalkwijk S, Konopnicki D, Rockstroh  J, Burger D, on behalf of the PANNA network

Published: Oral presentation at 19th edition of the International Workshop on Clinical Pharmacology of Antiviral Therapy, May 22nd-24th 2018, Baltimore.




Aug, 2018

REVIVE Webinar: Development of antibacterial drugs targeting specific pathogens


The Global Antibiotic Research & Development Partnership (GARDP) has announced that its third live webinar.

Title:  Antibacterial drugs: Clinical development for non-developers – Par 2: Development of antibacterial drugs targeting specific pathogens

revive-logo-new-tagline-no-bg-low-resDate and time: September 11th, 17:00-18:30 (CEST)

The webinar is on the platform REVIVE, an online space for the antimicrobial R&D community to educate, connect, and share good practice in how to conduct antimicrobial drug R&D.

To register for this live webinar, please click here.


Aug, 2018

Human Immunodeficiency Virus (HIV) – Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children


Authors: Rocca S, Zangari P, Cotugno N, et al.

Published in: J Pediatric Infect Dis Soc.2018; 28. doi:10

Background Assays to estimate human immunodeficiency virus (HIV) reservoir size require large amounts of blood, which represents a drawback especially in pediatric settings. We investigated whether HIV-antibody repertoire could estimate the viral reservoir size. Moreover, we assessed the magnitude of HIV-antibody response as a predictor of time of antiretroviral therapy (ART) initiation.

Methods Human immunodeficiency virus-antibody responses to 10 different viral proteins were evaluated by HIV Western blot (WB) kit and a WB score was assigned to each patient. Patients were classified in 2 subgroups based on the timing of ART initiation (early treated [ET], 0–24 weeks and late treated [LT], >24 weeks). Human immunodeficiency virus-deoxyribonucleic acid (DNA) was quantified using real-time quantitative polymerase chain reaction on total peripheral blood mononuclear cells. Logistic regression and principal component analysis were built on these data to test the ability of WB score to predict the expected value of HIV-DNA and the timing of ART initiation.

Results Sixty-nine perinatally HIV-infected children were evaluated. Reduced HIV-specific antibody responses and lower size of HIV-DNA were observed in ET compared with LT patients (P < .001 and P = .02, respectively). We found that WB score correlates with HIV-DNA (P = .032) and timing of ART initiation (P < .001). Based on the logistic regression analysis, we found that WB score can predict the HIV-DNA size and the timing of ART initiation with an Akaike information criterion of −118.13 and −151.51, respectively.

Conclusions Western blot score can estimate HIV-DNA size and timing of ART initiation in long-term virally suppressed children. This rapid, inexpensive, and easily reproducible tool can provide useful information to identify potential candidates for HIV remission studies.




Aug, 2018

AIDS 2018: Accelerating the development and uptake of the most needed drug formulations for children


The 22nd International AIDS Conference in Amsterdam, The Netherlands 23 – 27 July 2018 hosted the session “Accelerating the development and uptake of the most needed drug formulations for children”.

Martina Penazzato from the World Health Organization (WHO) introduced the Global Accelerator for Paediatric Formulations (GAP-f) which aims to promote a faster, more efficient and more focused approach to paediatric formulation development.

Carlo Giaquinto and Elaine J. Abrams contributed with a presentation on Prioritization and clinical research of priority formulations.

Thanks to all participants involved for their valuable collaboration. The event proved very useful indeed in drawing more attention to the important topic of developing appropriate paediatric drug formulations.

You can find the slide sets, the recording of the entire session and the pictures on the AIDS 2018 website.


Aug, 2018

WHO: interim guidance policy brief publication


The World Health Organisation has published updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV.

Update on antiretroviral regimens for treating and preventing HIV infection: Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment. New WHO interim guidelines contain recommendations regarding preferred first-line regimens for adults, adolescents and children initiating ART, which now include DTG and RAL.

Update on early infant diagnosis of HIV: In 2016, WHO recommended that HIV virological testing be used to diagnose HIV infection among infants and children younger than 18 months and that ART be started without delay while a second specimen is collected to confirm the initial positive virological test result.

Read the policy brief in full here.


Aug, 2018

PED-MERMAIDS has reached 50% of enrollment target!


We are delighted to announce that the study PED-MERMAIDS has surpassed 50% of the enrollment target of 1,000 patients. This is a great achievement and we extend our thanks to all the sites involved for their great work.

PED-MERMAIDS is part of the project PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics), an EU funded network for harmonized large-scale clinical research studies on infectious diseases, prepared to rapidly respond to any severe ID outbreak, providing real-time evidence for clinical management of patients and for informing public health responses.logoprepare

PREPARE is funded by the European Commission’s FP7 Programme under grant number 602525.


Aug, 2018

HIV specific IgM memory B-cells dominate in seronegative early-treated children


Authors: Cotugno N, Morrocchi E, Pepponi I, Rocca S, Cameron M, Rinaldi S, Di Cesare S, Pallikkuth S, Bernardi S, Klein N, Ananworanich J, Rossi P, Pahwa S, Palma P

Published25th Conference on Retroviruses and Opportunistic Infections, March 4th – 7th, 2018 – Boston. P_ 866

Abstract This fascinating study investigates whether HIV specific B cells persist in seronegative HIV infected seronegative patients and what are the associated gene signatures after re-encountering the virus.


We would like to update you on our recent activities